Abivax Rebounds 25% After Safety Data Eases Cancer Scare

Abivax has been the subject of persistent takeover speculation, with unverified rumors that several large pharmaceutical companies have shown interest. The safety signal had been seen as a barrier to M&A discussions. Tuesday's data may revive those conversations, if acquirers view the malignancy rates as manageable and consistent with other drugs in the class.

For the broader inflammatory bowel disease space, the data removes one risk factor that had been hanging over the clinical-stage asset. Large pharma firms have been active in the IBD space, seeking late-stage drugs with differentiated mechanisms. Obefazimod targets a sphingosine-1-phosphate receptor, a class that has attracted attention since the approval of other S1P modulators for ulcerative colitis. The safety profiles of these drugs have been a key point of differentiation.

The maintenance study data Monday covered only safety. The full efficacy readout, including remission rates and secondary endpoints, remains pending. That data will determine whether obefazimod can compete in a crowded market dominated by established biologics and newer oral drugs.

Abivax's cash position remains a constraint. The company ended the first quarter with around €80 million in cash and equivalents, according to its last filing. That would fund operations into the first quarter of 2025, based on the current burn rate. Without a partnership, royalty sale, or acquisition, the company will need to address its capital needs before the next major catalyst.

The 25% bounce Tuesday shows the market is willing to interpret the safety data positively. The stock's path from here depends on the integrity of the full Phase 3 data and the company's ability to secure non-dilutive funding. M&A speculation will also be a factor.